Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
Eugen Feist, Roy Fleischmann, Saeed Fatenejad, Д. В. Буханова, Sergey Grishin, Sofia Kuzkina, Michael E. Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen
Topics & Concepts
MedicineTolerabilityAdverse effectInternal medicineNeutropeniaRheumatoid arthritisMethotrexateClinical trialGastroenterologyToxicityRheumatoid Arthritis Research and TherapiesAcute Lymphoblastic Leukemia researchInflammatory Bowel Disease